KYTX KYTX
Company Profile ↓Company Overview
KYTX (KYTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +126.71% |
| 6 Months: | -8.28% |
| 3 Months: | -17.05% |
| 1 Month: | -21.07% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross7d ago
- RSI (14)47.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 32.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -11.45M | -13.30M | -16.28M | -29.36M | -33.44M | -38.77M | -47.41M | -44.41M | -38.73M | -41.37M |
| Net Income | -11.14M | -13.09M | -15.46M | -26.69M | -28.80M | -34.49M | -44.63M | -42.08M | -36.79M | -39.73M |
| Diluted EPS | -12.10 | -20.86 | -23.27 | -1.12 | -0.67 | -0.80 | -1.03 | -0.97 | -0.85 | -0.66 |
| R&D Expense | 8.71M | 10.40M | 13.64M | 22.48M | 27.32M | 29.19M | 37.43M | 35.82M | 30.46M | 30.07M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -62.41M | -142.60M | -169.83M |
| Net Income | -60.37M | -127.48M | -161.31M |
| Diluted EPS | -89.61 | -3.33 | -3.64 |
| R&D Expense | 49.92M | 112.47M | 133.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 75.19M | 304.64M | 293.83M |
| Total Equity | -74.00M | -13.14M | 266.59M | 232.28M |
| Cash & Equivalents | - | 34.65M | 96.62M | 124.09M |
| Total Liabilities | - | 26.02M | 38.06M | 61.55M |
| Current Liabilities | - | 19.86M | 33.76M | 36.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -52.41M | -114.25M | -153.71M |
| Investing Cash Flow | -8.79M | -160.90M | 40.02M |
| Financing Cash Flow | 58.12M | 337.11M | 141.17M |
| Capital Expenditure | -621.00K | -2.21M | -5.00K |
| Free Cash Flow | -53.03M | -116.45M | -153.72M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 459.4% | -47.8% | -69.4% |
| ROCE % | -112.8% | -52.6% | -66.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KYTX
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-celEMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX…
Kyverna Therapeutics Sinks 13%: Here’s Why
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or the start of a painful unwind.…
Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond
Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The recent quarter began against the backdrop of the war in the Middle East and concerns about AI disruption i…
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointmen…
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-cel continues to demonstrate a well-tole…
KYTX — Frequently Asked Questions
What is the current share price of KYTX?
As of 2026-08-05 17:25 PDT, KYTX trades at $7.64 on NASDAQ/NYSE. Its 52-week range is $3.02 to $11.25.
What is the P/E ratio of KYTX?
KYTX trades at a trailing price-to-earnings (P/E) ratio of -2.10.
What is the return on equity (ROE) of KYTX?
KYTX has a return on equity (ROE) of -69.45%. Its return on capital employed (ROCE) is -65.99%.
Is KYTX a good stock to buy?
This page provides a data-driven analysis of KYTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.